Doximity Stock News

I rate Doximity a buy with a price target of $65, reflecting a 24% upside due to strong Q2 earnings and favorable industry trends. Doximity's Q2 earnings showed impressive revenue growth, margin expansion, and a revised forecast of 36% CAGR in revenue and 74% CAGR in Adjusted EBITDA. Positioned at the intersection of healthcare trends, Doximity offers cost-saving solutions that align with indus...

The market loved what it saw from Doximity's second-quarter earnings.

Doximity (DOCS) shares jumped nearly 40% in premarket trading Friday after the medical tech company's earnings and outlook came in above what analysts expected.

The online medical platform reported quarterly revenue of $136.8 million and earnings of 30 cents a share, beating analysts expectations.

Doximity, Inc. (NYSE:DOCS ) Q2 2025 Earnings Conference Call November 7, 2024 5:00 PM ET Company Participants Perry Gold - Vice President of Investor Relations Jeff Tangney - Co-Founder and CEO Anna Bryson - Chief Financial Officer Nate Gross - Co-Founder and Chief Strategy Officer Conference Call Participants Glen Santangelo - Jefferies Johnathan McCary - Raymond James Stephanie Davis - Barcla...

This telehealth technology provider is holding above its 50-day moving average. The company reports its next earnings on Nov. 7.

SAN FRANCISCO--(BUSINESS WIRE)--Doximity, Inc. (NYSE:DOCS), the leading digital platform for U.S. medical professionals, today announced it will report financial results for its fiscal second quarter ended September 30, 2024 after market close on November 7, 2024. Doximity will host a conference call and webcast at 2:00 p.m. PT (5:00 p.m. ET) to discuss the financial results. To listen to a liv...

NEW YORK--(BUSINESS WIRE)--Scott+Scott Attorneys at Law LLP (“Scott+Scott”), an international securities and consumer rights litigation firm, is investigating whether the leadership of Doximity, Inc. (“Doximity”) (NYSE: DOCS) breached their fiduciary duties to Doximity and its shareholders. CLICK HERE TO LEARN MORE Scott+Scott is investigating whether members of Doximity's board of directors or...